469 related articles for article (PubMed ID: 27536673)
1. Management of Membranous Nephropathy in Western Countries.
Alfaadhel T; Cattran D
Kidney Dis (Basel); 2015 Sep; 1(2):126-37. PubMed ID: 27536673
[TBL] [Abstract][Full Text] [Related]
2. Management of Membranous Nephropathy in Asia.
Xu J; Hu X; Xie J; Chen N
Kidney Dis (Basel); 2015 Sep; 1(2):119-25. PubMed ID: 27536672
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
4. Overview of current and alternative therapies for idiopathic membranous nephropathy.
Tran TH; J Hughes G; Greenfeld C; Pham JT
Pharmacotherapy; 2015 Apr; 35(4):396-411. PubMed ID: 25884528
[TBL] [Abstract][Full Text] [Related]
5. A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China.
Wu L; Lai J; Ling Y; Weng Y; Zhou S; Wu S; Jiang S; Ding X; Jin X; Yu K; Chen Y
Med Sci Monit; 2021 Feb; 27():e930097. PubMed ID: 33550324
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
7. Response to immunosuppressive therapy in PLA
Wang J; Xie Q; Sun Z; Xu N; Li Y; Wang L; Liu S; Xue J; Hao CM
BMC Nephrol; 2017 Jul; 18(1):227. PubMed ID: 28693446
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.
Liang J; Hao W; Xia F; Zhao Z; Wu Y; Yu F; Hu W; Fang X; Liu W
Ren Fail; 2023 Dec; 45(1):2212081. PubMed ID: 37194712
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
Chen Y; Deng Y; Ni Z; Chen N; Chen X; Shi W; Zhan Y; Yuan F; Deng W; Zhong Y
Am J Kidney Dis; 2013 Dec; 62(6):1068-76. PubMed ID: 23810688
[TBL] [Abstract][Full Text] [Related]
10. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
11. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.
Rojas-Rivera JE; Carriazo S; Ortiz A
Clin Kidney J; 2019 Oct; 12(5):629-638. PubMed ID: 31583088
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults.
Xie G; Xu J; Ye C; Chen D; Xu C; Yang L; Ma Y; Hu X; Li L; Sun L; Zhao X; Mao Z; Mei C
PLoS One; 2012; 7(9):e44330. PubMed ID: 22957065
[TBL] [Abstract][Full Text] [Related]
13. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
[TBL] [Abstract][Full Text] [Related]
14. From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?
Stai S; Lioulios G; Christodoulou M; Papagianni A; Stangou M
J Nephrol; 2023 Mar; 36(2):551-561. PubMed ID: 36450999
[TBL] [Abstract][Full Text] [Related]
15. Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian population.
Ardalan M; Ghafari A; Hamzavi F; Nasri H; Baradaran B; Majidi J; Nikbin B
J Nephropathol; 2013 Oct; 2(4):241-8. PubMed ID: 24475456
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA
J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
18. Traditional Chinese medicine for idiopathic membranous nephropathy: A systematic review and meta-analysis.
Shan W; Guan H; Gu H; Wang R; Huang X; Li P; Xie Y; Bao K; Qin X
Heliyon; 2024 Apr; 10(7):e28836. PubMed ID: 38596093
[TBL] [Abstract][Full Text] [Related]
19. [Modern view on treatment of membranous nephropathy].
Bobkova IN; Kamyshova ES
Ter Arkh; 2020 Jul; 92(6):99-104. PubMed ID: 33346502
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis.
Zheng Q; Yang H; Liu W; Sun W; Zhao Q; Zhang X; Jin H; Sun L
BMJ Open; 2019 Sep; 9(9):e030919. PubMed ID: 31511292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
